15156 Autoimmune cutaneous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the FDA Adverse Event Reporting System from the Research on Adverse Drug Events and Reports program

Abstract

Background: Autoimmune cutaneous disorders (AICD have been inconsistently reported during treatment with PD-1 (nivolumab, pembrolizumab, cemiplimab) and PD-L1 (atezolizumab, avelumab, durvalumab) checkpoint inhibitors. Case reports exist in the literature for 2 AICDs, vitiligo (VI) and lichen planus (LP), but an association with a PD1/PDL1 agents has not been well substantiated. The aim of this study was to determine if an association exists for these AICDs and PD-1 and PD-L1 inhibitors within a large database, the FDA Adverse Event Reporting System (FAERS).